(Q51036136)

27 March 2018

title

HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. (English)

1 reference

27 March 2018

0 references

0 references

8

Steven G Reed

1 reference

27 March 2018

author name string

Jinyao Li

1

1 reference

27 March 2018

Antonio Valentin

2

1 reference

27 March 2018

Viraj Kulkarni

3

1 reference

27 March 2018

Margherita Rosati

4

1 reference

27 March 2018

Rachel Kelly Beach

5

1 reference

27 March 2018

Candido Alicea

6

1 reference

27 March 2018

Drew Hannaman

7

1 reference

27 March 2018

Barbara K Felber

9

1 reference

27 March 2018

George N Pavlakis

10

1 reference

27 March 2018

language of work or name

English

0 references

publication date

26 April 2013

1 reference

27 March 2018

published in

Vaccine

1 reference

27 March 2018

volume

31

1 reference

27 March 2018

issue

36

1 reference

27 March 2018

page(s)

3747-3755

1 reference

27 March 2018

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Comparison of immune responses generated by optimized DNA vaccination against SIV antigens in mice and macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

7 January 2021

Toward an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Intradermal immunization improves protective efficacy of a novel TB vaccine candidate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Use of defined TLR ligands as adjuvants within human vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Induction of active immune suppression by co-immunization with DNA- and protein-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Enhanced contraceptive response by co-immunization of DNA and protein vaccines encoding the mouse zona pellucida 3 with minimal oophoritis in mouse ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Intranasal co-administration with the mouse zona pellucida 3 expressing construct and its coding protein induces contraception in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Efficient induction of CD25- iTreg by co-immunization requires strongly antigenic epitopes for T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Induction of adaptive T regulatory cells that suppress the allergic response by coimmunization of DNA and protein vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Caveolin-1-mediated negative signaling plays a critical role in the induction of regulatory dendritic cells by DNA and protein coimmunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Protein/DNA vaccine-induced antigen-specific Treg confer protection against asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Treatment of autoimmune ovarian disease by co-administration with mouse zona pellucida protein 3 and DNA vaccine through induction of adaptive regulatory T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

An immunotherapeutic treatment against flea allergy dermatitis in cats by co-immunization of DNA and protein vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Protective response against type 1 diabetes in nonobese diabetic mice after coimmunization with insulin and DNA encoding proinsulin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

The successful immune response against hepatitis C nonstructural protein 5A (NS5A) requires heterologous DNA/protein immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Dengue tetravalent DNA vaccine increases its immunogenicity in mice when mixed with a dengue type 2 subunit vaccine or an inactivated Japanese encephalitis vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.037

inferred from DOI database lookup

7 January 2021

based on heuristic

Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23624057

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.04.037

1 reference

27 March 2018

PubMed ID

23624057

1 reference

27 March 2018